中國核能科技(00611.HK)開發濟源儲能電站 採購及施工開支共涉近2.05億人幣
中國核能科技(00611.HK)公佈,公司之間接全資附屬「南京中核」與遠景能源(作爲供應商)訂立儲能系統設備採購協議。據此「南京中核」同意購買,而遠景能源同意以採購價1.416億元人民幣(下同)出售若幹儲能系統設備;及與河北靖峽(作爲承建商)就安裝及建設服務訂立合同金額爲6,336萬元的施工建設協議。採購及施工開支共涉近2.05億元。
儲能系統設備採購協議及施工建設協議項下擬進行的交易是爲了開發濟源儲能電站。預計濟源儲能電站將於2025年8月30日或之前併網發電。建造完成後,濟源儲能電站將由集團擁有及營運。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.